| Caitlin Justine Koelling, DPM | |
|
3190 E Meridian Park Loop Ste 205, Wasilla, AK 99654-7422 | |
| (907) 569-3668 | |
| (907) 569-3669 |
| Full Name | Caitlin Justine Koelling |
|---|---|
| Gender | Female |
| Speciality | Podiatry |
| Experience | 6 Years |
| Location | 3190 E Meridian Park Loop Ste 205, Wasilla, Alaska |
| Accepts Medicare Assignments | May be. She may accept the Medicare-approved amount; you may be billed for more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1063917177 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 213ES0103X | Podiatrist - Foot & Ankle Surgery | 173700 (Alaska) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Mat-su Regional Medical Center | Palmer, AK | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Matt A. Heilala, Dpm Inc. | 3779496294 | 11 |
News Archive
Calistoga Pharmaceuticals, Inc., the leader in the development of isoform-selective phosphatidylinositol 3 kinase (PI3K) inhibitors for the treatment of cancer and inflammatory diseases, today announced updated clinical data on CAL-101, the Company's oral, delta selective PI3K inhibitor, presented during two oral presentations at the 51st American Society of Hematology Annual Meeting in New Orleans.
Merz Pharmaceuticals, LLC, maker of XEOMIN, a botulinum toxin type A free from accessory proteins, today announced the launch of the "Make Your Mark" campaign.
Reducing systolic blood pressure to less than 140 mmHg has offered no benefits over standard care for patients with acute intracerebral haemorrhage in the ATACH-2 trial.
A team of Monash University researchers led by Professor James Whisstock has made a major breakthrough in the international fight against malaria, which claims the life of a child across the world every 30 seconds.
› Verified 1 days ago
| Provider Name | Matt A. Heilala, Dpm Inc. |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1316046790 PECOS PAC ID: 3779496294 Enrollment ID: O20031111000251 |
News Archive
Calistoga Pharmaceuticals, Inc., the leader in the development of isoform-selective phosphatidylinositol 3 kinase (PI3K) inhibitors for the treatment of cancer and inflammatory diseases, today announced updated clinical data on CAL-101, the Company's oral, delta selective PI3K inhibitor, presented during two oral presentations at the 51st American Society of Hematology Annual Meeting in New Orleans.
Merz Pharmaceuticals, LLC, maker of XEOMIN, a botulinum toxin type A free from accessory proteins, today announced the launch of the "Make Your Mark" campaign.
Reducing systolic blood pressure to less than 140 mmHg has offered no benefits over standard care for patients with acute intracerebral haemorrhage in the ATACH-2 trial.
A team of Monash University researchers led by Professor James Whisstock has made a major breakthrough in the international fight against malaria, which claims the life of a child across the world every 30 seconds.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Caitlin Justine Koelling, DPM 2250 E 42nd Ave # 200, Anchorage, AK 99508-5202 Ph: (907) 569-3668 | Caitlin Justine Koelling, DPM 3190 E Meridian Park Loop Ste 205, Wasilla, AK 99654-7422 Ph: (907) 569-3668 |
News Archive
Calistoga Pharmaceuticals, Inc., the leader in the development of isoform-selective phosphatidylinositol 3 kinase (PI3K) inhibitors for the treatment of cancer and inflammatory diseases, today announced updated clinical data on CAL-101, the Company's oral, delta selective PI3K inhibitor, presented during two oral presentations at the 51st American Society of Hematology Annual Meeting in New Orleans.
Merz Pharmaceuticals, LLC, maker of XEOMIN, a botulinum toxin type A free from accessory proteins, today announced the launch of the "Make Your Mark" campaign.
Reducing systolic blood pressure to less than 140 mmHg has offered no benefits over standard care for patients with acute intracerebral haemorrhage in the ATACH-2 trial.
A team of Monash University researchers led by Professor James Whisstock has made a major breakthrough in the international fight against malaria, which claims the life of a child across the world every 30 seconds.
› Verified 1 days ago
Alaska Foot & Ankle Specialists Podiatrist Medicare: Medicare Enrolled Practice Location: 3190 E Meridian Park Loop Ste 205, Wasilla, AK 99654 Phone: 907-569-3668 |